29 results about "Succinylation" patented technology

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K17 site succinylation modification and application. Experiments show that the 17-site lysine of the PGK1 protein has succinylation modification (PGK1 K17su), and the existence of the modification is confirmed through a specific succinylation modified antibody for the first time. Further, it is found that PGK1 K17su can weaken lung cancer cell oxidative phosphorylation and promote glycolysis metabolism by inhibiting lung cancer cell mitochondrial generation, and functional experiments prove that PGK1 K17 succinylation modification promotes proliferation and migration of lung cancer cells.

The invention relates to the technical field of biological medicine, in particular to a specific antibody for detecting or targeting ALDOA-K13 succinylation modification and application of the specific antibody. The specific antibody for detecting or targeting ALDOA-K13 succinylation modification can be specifically combined with a succinylation modification site of 13th lysine of human ALDOA protein, and is not combined with ALDOA of an unmodified type or other modified types. The invention provides a specific antibody for detecting or targeting ALDOA-K13 succinylation modification for the first time, and fills the blank of existing detection tools. The antibody not only has high specificity and sensitivity, but also can be used for developing a novel tumor diagnosis and prognosis detection method.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K6 site succinylation modification and application. Experiments show that the 6th lysine of the PGK1 protein has succinylation modification (PGK1 K6su), and the existence of the succinylation modification at the 6th lysine is confirmed through immunoprecipitation experiments; cell function experiments prove that the PGK1 K6su enhances lung cancer cell migration and multiplication capacity and promotes lung cancer progression. A small molecule compound diammonium glycyrrhizinate aiming at the PGK1 K6 site is further obtained through computer-assisted screening, and subsequent experiments find that the compound can inhibit proliferation and migration of lung cancer cells by reducing the succinylation modification level of the lung cancer cells PGK1 K6.

The invention relates to the technical field of food, in particular to a method for preparing gel based on succinylation modified rice protein alkali heat induction. The preparation method comprises the following steps: firstly, acylating rice protein by adopting succinic anhydride to prepare rice protein with different acylation degrees; the influence of different alkaline solutions and alkaline environments with different pH values on the performance of inducing the rice protein to prepare the gel is further investigated. Compared with a traditional alkali heat induction process, the brand new rice protein gel preparation process provided by the invention is milder and safer. The application range of the rice protein in the food industry is expanded, and meanwhile, an important foundation is laid for developing safe, nutritional and palatable foods easy to swallow.

The present technique pertains to a method of preparation of a succinylated collagen-fibrinogen hydrogel and a succinylated collagen-fibrinogen hydrogel prepared thereby. The method of preparation of a succinylated collagen-fibrinogen hydrogel according to the present technique can produce a collagen-based bio-substance in a simple process, wherein collagen can be prevented from being entangled and an improvement can be brought about in hydrophilicity, cell growth rate, cell compatibility, and cell diffusion capability, whereby the collagen-based bio-substance exhibits excellent biocompatibility in vivo.

The invention relates to the technical field of animal feed preparation, in particular to animal feed rich in protein and a preparation method thereof. The animal feed provided by the invention is prepared by taking the chemically induced and intensively cultured microalgae as a protein source, modifying the protein source through succinylation and then synergistically compounding the modified protein source with a composite chelating agent. The content of microalgae protein in the feed prepared by the method reaches 20% or above of dry weight, the total protein content of the feed is greater than or equal to 28%, the protein digestion and absorption rate of animals is increased to 88% or above, and meanwhile, the animal immune function is effectively enhanced.

The application provides a high-temperature-resistant and gastric acid-resistant probiotic preparation and a preparation method thereof, and the preparation comprises a probiotic core layer and a shell layer covering the same, and the shell layer comprises succinyl-modified food leaf protein assisted by ultrasonic pretreatment, peach gum polysaccharide and soybean lecithin. The application constructs a single-layer protection system with excellent responsiveness by performing specific functional modification on the food leaf protein and synergizing the food leaf protein with the peach gum polysaccharide and the soybean lecithin. The preparation can significantly improve the survival rate of probiotics during processing, storage and simulated gastrointestinal digestion, and especially realizes excellent gastric acid resistance and intestinal targeting release performance, and the process is simple and suitable for embedding and protecting various probiotics.

The invention discloses a preparation method of an easy-to-swallow shiitake mushroom pork product, which comprises the following steps: pretreating shiitake mushrooms, carrying out multi-stage fermentation to obtain a high-flavor shiitake mushroom fermented product, pretreating pork to prepare meat paste, mixing the meat paste with the shiitake mushroom fermented product, folic acid-succinylated konjac glucomannan, soybean protein isolate and other raw materials, stirring, molding, cooking, refrigerating and packaging to obtain the easy-to-swallow shiitake mushroom pork product. According to the invention, shiitake mushrooms are subjected to multi-stage fermentation treatment to obtain a high-flavor fermented product, and folic acid and succinylated compound modified konjac glucomannan are adopted to improve the instant solubility and water wettability of the shiitake mushrooms; the modified konjac glucomannan and the soybean protein isolate in the easy-to-swallow mushroom product form a continuous gel network composite matrix which is soft, uniform and high in cohesion, so that the product is smooth in texture, high viscosity and cohesion are maintained under low shearing force of an oral cavity, the viscosity is reduced under high shearing force during swallowing, low swallowing resistance, high cohesion and difficulty in residue are realized, and the bucking risk is reduced. Meanwhile, the product is rich in flavor, fresh and fragrant, high in nutrition density and suitable for people with dysphagia to eat.

This invention relates to the field of biomedical technology, disclosing succinylated modified RAD51 protein, formulations for promoting RAD51 succinylation, and their applications. The method includes: seeding and culturing cells and transfecting them with a tagged RAD51 expression plasmid; adding sodium succinate and an HDAC11 inhibitor to the culture medium for continued culturing to allow intracellular modification accumulation; collecting the supernatant after cell lysis and incubating it with magnetic beads containing anti-tag antibodies under cold conditions; washing and eluting with an elution buffer containing the tagged peptide; performing immunoblotting analysis using antibodies that specifically recognize the modified site to obtain the succinylated modified RAD51 protein. This invention, by adding sodium succinate and an HDAC11 inhibitor, provides a substrate and blocks the demodification pathway. Combined with magnetic bead purification and competitive elution, it avoids disrupting the protein conformation, obtaining a protein that retains its native activity and has a high level of modification, providing a core component for screening targeted drugs.

The invention specifically discloses an acute myelogenous leukemia prognostic marker and application thereof, and relates to the technical field of biological medicines. The invention provides an application of a protein lysine succinylation modification level as an acute myelogenous leukemia diagnosis and / or prognosis marker, and clinical data, cell experiments and animal experiments prove that the protein lysine succinylation modification level is related to AML prognosis and is a supplement of an existing prognosis system. Ksuc can be detected through a multi-parameter flow type technology, the method is simple, convenient and rapid, the experimental period is only several hours, Ksuc can be obtained when conventional immune typing detection is carried out at the beginning of diseases, and the experimental period is shorter than that of existing prognosis factors adopting next-generation sequencing, traditional PCR and the like. The invention provides a theoretical basis and an experimental basis for developing a new treatment strategy, and has good clinical transformation and clinical application prospects.

Protein polyurethane alloys including one or more succinylated proteins dissolved within one or more polyurethanes. The protein polyurethane alloys may have one or more mechanical properties that are superior to the polyurethane in the absence of protein. The protein polyurethane alloys may be incorporated into a layered material including one or more protein polyurethane alloy layers.

The present application belongs to the field of biological medicine, and particularly relates to a teriparatide oral preparation, a preparation method and application thereof. Specifically, the present application provides a teriparatide oral preparation, which comprises exosome-encapsulated teriparatide, wherein the surface of the exosome is grafted with succinylated epsilon-polylysine. The present application uses exosomes grafted with succinylated epsilon-polylysine to encapsulate and orally deliver teriparatide, and it is found that the exosomes can realize the release of teriparatide in the intestinal tract, and can also promote the intestinal wall permeability of teriparatide, thereby significantly improving the bioavailability of the oral teriparatide.

The application belongs to the field of drug delivery nanotechnology, and provides a method for preparing cubic lipid nanoparticles encapsulating small interfering ribonucleic acid and application thereof. The application adopts a trinity design of ion complex pre-assembly of succinylated glycerol monooleate and cationic lipids, space stabilization of poloxamer 407, and rapid particle formation by microfluidics, realizes stable construction of internal nanostructure of inverse bicontinuous cubic phase, encapsulation of small interfering ribonucleic acid in water channel network with high drug loading, long-term stability of colloids under physiological ion strength conditions, and excellent batch consistency, solves the technical contradictions of existing lipid nanometer delivery systems, such as difficulty in giving consideration to low polydispersion and batch consistency, mutual restraint of cationic complex strength and colloidal stability, and difficulty in synergistic optimization of high drug loading and stability of cubic phase structure under high solid content microfluidic conditions, and has wide application value in gene therapy and nucleic acid drug delivery.

This invention belongs to the field of biomedical material preparation technology, specifically disclosing a method for moist heat sterilization of recombinant collagen fillers. The method includes: preparing a protective solution from modified trehalose and proline, then mixing it with homogenized recombinant collagen hydrogel, followed by staged temperature-controlled moist heat sterilization. This invention modifies trehalose by succinylation, introducing carboxyl groups onto the trehalose molecule, enabling electrostatic interactions with cationic groups on the surface of collagen molecules. During moist heat sterilization, free proline guides the heat-denatured collagen to refold into its natural triple helix structure. The preheating stage allows the collagen to gradually adapt to the thermal environment, avoiding conformational shock damage caused by sudden temperature increases, effectively shortening the high-temperature sterilization time, and significantly reducing the cumulative heat effect on molecular structure. This method is simple to operate, requires no special equipment, and has good prospects for industrial application.

The invention belongs to the technical field of biological medicines, and particularly relates to a targeted CANX and SIRT7 combined polypeptide inhibitor and application thereof in lung adenocarcinoma radiation resistance treatment. The polypeptide has a sequence TKPPSRRPKL (SEQ ID NO: 1), and can be competitively combined with CANX protein and block succinylation modification of SIRT7 on the CANX protein, so that the localization and function of CANX in MAM are recovered, mitochondrial metabolism reprogramming is reversed, and the radiosensitivity of lung adenocarcinoma cells is enhanced. Experiments show that the polypeptide can significantly inhibit the combination of CANX and SIRT7 in vitro and improve the radiosensitivity of radiation-resistant lung adenocarcinoma cells. The invention provides a new targeting strategy and drug candidate for treatment of lung adenocarcinoma radiation resistance.

The invention discloses an esophageal cancer immune data prediction device and equipment based on a tumor marker and a storage medium, and relates to the technical field of electric digital data processing, the device constructs a more comprehensive tumor microenvironment evaluation system through ctDNA 5hmC epigenome sequencing and tumor tissue succinylation modification level analysis, and the tumor microenvironment evaluation system is used for evaluating the esophageal cancer immune data. The problem that a traditional biomarker (such as PD-L1 expression and tumor mutation load) is poor in prediction effect is solved; secondly, dynamic ctDNA data are processed through a time sequence channel and succinylation scores are processed through a static channel through a double-channel LSTM-Cox hybrid model, and advantage complementation of the two kinds of data is achieved; and finally, quantizing complex immune data into three intuitive good / general / poor scoring intervals to provide a clear treatment decision basis for clinicians. The scoring system can obviously reduce the invalid treatment rate.

The present application belongs to the technical field of modified yeast protein, and particularly relates to a double modified yeast protein purification product, a heat-induced gel and preparation and application thereof. The solubility of the double modified yeast protein purification product is greater than 15.00%, the turbidity is less than 1.70, the particle size is less than 1500.00 nm, the Zeta potential is less than -47.00 mV, and the succinylated degree is greater than 20.00%. The double modified yeast protein purification product is obtained by mixing yeast protein powder suspension with a pH of 7.0-11.0 and succinic anhydride at a dry matter mass ratio of 0.1:1-0.5:1, then performing succinylation reaction, ultrasonic treatment under a ultrasonic power of 200-600 W, and dialysis. The present application promotes specific conformational changes and interactions of modified yeast protein molecules in the double modified yeast protein purification product by controlled heat-induced technology, and a double modified yeast protein heat-induced gel product with good gel performance, transparency, water holding capacity and gel strength is prepared.

This invention, entitled "Temperature- and pH-Sensitive BPA-Targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA Core-Shell Polymeric Nanoparticles Capable of Forming COF Structures in the BNCT Therapeutic Method," pertains to an anti-cancer pharmaceutical composition utilizing novel drug delivery methods. The application of the novel BNCT method is advantageous for cancers such as glioblastoma due to the challenge of crossing the blood-brain barrier. BNCT is a dual and targeted method wherein cancer cells, following the accumulation of ¹⁰B, are irradiated with thermal neutrons. Loading boron-containing compounds into nanoparticles can deliver a high concentration of boron to human glioblastoma cells. Temperature- and pH-sensitive nanoparticles of succinylated chitosan–poly(N-isopropylacrylamide) targeted with BPA are our concept for achieving endocytosis via sialic acid receptors on the surface of glial cells and for the targeted delivery of boron to these cells. By designing temperature- and pH-sensitive, BPA-targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA core-shell polymeric nanoparticles with the capability of forming COF structures in order to simultaneously deliver BPA and FPBA, we aim to utilize the polymeric boron content to perform treatment via the BNCT method. Consequently, damage to healthy cells is reduced to a minimum, and even to zero.

The invention relates to application of CSRP1 as a target spot in regulation and control of cancer-related fibroblasts and treatment of high-grade serous ovarian cancer, and belongs to the technical field of biological medicine. A large number of experiments prove that CSRP1 is expression down-regulation in an HGSOC sample; low expression of CSRP1 in CAF is closely related to poor prognosis of HGSOC patients, and CSRP1 expressed in CAF limits growth and metastasis of tumors by inhibiting activation of CAF. And the lysine 141 site (K141) is the most critical Ksucc site of the CSRP1 (CSRP1). The CPT1A reduces the expression level of the CSRP1 in the CAF by inducing the interaction between the succinylation modification of the K141 site of the CSRP1 and the ubiquitination modification of the K173 site of the CSRP1. Overexpression of the CSRP1 can change exosome protein components secreted by the CAF, so that communication between the exosome-mediated CAF in the HGSOC and tumor cells is influenced. The invention reveals the importance of Ksucc in the progress of HGSOC, and CSRP1 targeting CAF may have a therapeutic value.

This invention discloses the application of the compound pimozide in combination with metronidazole in the preparation of a drug for improving oocyte quality and treating endometriosis-related fertility disorders, belonging to the field of biomedical technology. The efficacy of this invention was verified by constructing mouse models of endometriosis driven by pathogenic *Prevotella bisporus* and mouse models of ovarian endometriosis. Experimental results showed that the combined administration significantly eliminated *Prevotella bisporus* colonizing ectopic lesions, reduced succinic acid content in both eutopic and ectopic lesions, decreased the succinylation level of lysine residue 195 of the ACADVL protein, reduced the fluidity of primary endometrial epithelial cell membranes, reduced the volume and weight of endometriotic lesions, and improved oocyte spermatogenesis, ovulation rate, and litter size. This invention solves the problem that existing therapies cannot simultaneously control endometriosis lesions and protect reproductive function, providing a new, safe, and effective combined treatment option for patients with endometriosis and infertility.

The invention provides traditional Chinese medicine nanoparticles for preventing and treating chicken coccidiosis and a preparation method and application thereof, and relates to the technical field of traditional Chinese veterinary medicines. Wherein the medicine component is composed of a first decoction and a second decoction, the first decoction is obtained by decocting astragalus membranaceus and bighead atractylodes rhizome, the second decoction is obtained by decocting antifebrile dichroa and artemisia apiacea, and the first decoction and the second decoction are respectively combined and concentrated to form a unified medicine component according to a preset proportion; the response carrier comprises succinylated chitosan and an azobenzene derivative cross-linked polymer containing azo bonds, and the drug components are embedded in the response carrier to form the traditional Chinese medicine nanoparticles with core-shell structures; the succinylated chitosan is swelled in an acid environment, and azo bonds are structurally changed under the action of azo reductase, so that the traditional Chinese medicine nanoparticles are easier to release medicine components in a chicken coccidiosis related intestinal environment; the invention further provides a preparation method of the traditional Chinese medicine nanoparticles and application of the traditional Chinese medicine nanoparticles in preparation of veterinary medicine preparations or feed additives for preventing and treating chicken coccidiosis.

The present disclosure generally relates to systems and methods for soluble particle, e.g., micrometer or sub-micrometer- sized particles s. Certain embodiments are generally directed to relatively small particles or microbubbles that can be administered to a subject, e.g., to treat or prevent hypoxia. The particles may include a shell surrounding a gas core, e.g., containing air or oxygen. In some cases, the particles may be highly soluble, for example, such that they can dissolve following administration to a subject. In some embodiments, the particles may comprise polymers such as dextran, starch, and / or other materials. In some cases, the polymer may have a molecular weight of less than 12 kDa, and / or the polymer may be succinylated and / or acetylated. Other embodiments are generally directed to methods of making or using such particles, methods of administrating such particles to a subject, pharmaceutical compositions or kits comprising such particles, or the like.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a refreshing and anti-fatigue traditional Chinese medicine composition and a preparation method thereof. The invention discloses a refreshing and anti-fatigue traditional Chinese medicine composition. Comprising succinylated pachymaran, an ethyl cellulose aqueous dispersion, acetyl tributyl citrate, polyoxyethylene sorbitan monooleate, an ethanol aqueous solution, chitosan oligosaccharide, ginsenoside Rg1 nano-micelles, polyvinylpyrrolidone, deionized water, pseudo-ginseng powder, ginseng powder, a pachymaran extract, a Chinese wolfberry fruit polysaccharide extract and a lotus plumule alkali extract. The composition is prepared from microcrystalline cellulose, cross-linked povidone, colloidal silicon dioxide and magnesium stearate. According to the refreshing and anti-fatigue traditional Chinese medicine composition disclosed by the invention, the inner layer directly forms a nano-fiber net film with an ultra-large specific surface area on the surface of the tablet core through an electrostatic spinning technology, and the nano-fiber net film can generate an extremely strong capillary action after meeting water, so that a rapid disintegration effect is realized.

The invention relates to the technical field of medicine, and particularly discloses a polypeptide-containing metagen bacteriostatic spray and a preparation method thereof.The active ingredient of the spray comprises a compound formed by lactobacillus metagen and succinylated epsilon-polylysine wrapped by nano-liposomes, the modification degree is 15%-25%, the mass ratio of lactobacillus metagen to succinylated epsilon-polylysine is 1: 0.3-1: 0.8, and the pH value is 7-8. And the particle size D90 of the spray is less than 50 microns. The preparation method comprises the following steps: preparing modified polypeptide, extracting post-generation by using dual-critical carbon dioxide, wrapping nano-liposome by using a pH gradient method, and preparing liquid in a mixing tank and filling. According to the mixing tank, an eccentric stirring structure is adopted to form three-dimensional flow, deposition is prevented through a bottom stirring frame, inert gas is introduced through an annular gas pipe for protection, and gridding cleaning is conducted on the inner wall of the tank body through a wall scraping structure. According to the invention, the compatibility of components is improved through polypeptide modification, the activity of metagen is retained through dual-critical extraction, and the problems of non-uniform mixing and wall adhesion of materials are solved by optimizing the structure of the mixing tank.

Examination of a test sample to determine the presence or quantity of succination of proteins is described. Examination can be via protein hydrolysis in total succination determination or via enzymatic digestion of isolated proteins and determination of the presence or quantity of modified peptides. The methods can be utilized for determination of excessive succination of lymph system proteins, which can be utilized in prevention or early detection of lymphopenia. Methods can be utilized for test samples of subjects under treatment with dimethyl fumarate suffering from multiple sclerosis. Methods can be utilized as a determination that treatment of the subject with DMF should be slowed or stopped.

The present invention relates to a mucoadhesive polymeric prodrug comprising a partially succinated polyvinyl alcohol (PVA-SA) with adjusted amount of hydroxyl and carboxyl pendant groups, which form an ester and / or amide linkage with amino and / or carboxyl and / or hydroxyl groups of biologically active compounds such as proteins, peptides, synthetic chemical, or natural products compounds (e.g. doxorubicin as an antitumor agent and antifibrotic drug). Preferably, said biologically active compounds are cysteamine (CYS) as the aminothiol compound and one compound selected from the group consisting of doxorubicin (DOX), ketoprofen (KETO), or 4-hydroxybenzyl alcohol (HBA). Moreover, the simultaneous presence of both hydroxyl and carboxyl groups in the partially succinated polyvinyl alcohol (PVA-SA) chain of the prodrug enables the self-assembled formation of 50-260 nm particles from the linear macromolecules and thus the drug release can be prolonged or adjusted. The present invention also relates to improving the mucoadhesive properties of the polymeric prodrug by the regulation of the amount of conjugated aminothiol compound. Further, the present invention relates to the method for producing said mucoadhesive polymeric prodrug, and nanoparticles of the said mucoadhesive polymeric prodrug.

The invention belongs to the technical field of modified yeast protein, and particularly relates to a purified product of double-modified yeast protein, heat-induced gel as well as preparation and application of the purified product and the heat-induced gel. The solubility of the double modified yeast protein purified product is greater than 15.00%, the turbidity is less than 1.70, the particle size is less than 1500.00 nm, the Zeta potential is less than-47.00 mV, and the succinylation degree is greater than 20.00%. The method comprises the following steps: mixing a yeast protein powder suspension with the pH value of 7.0-11.0 with succinic anhydride according to the dry matter mass ratio of succinic anhydride to yeast protein powder of 0.1: 1-0.5: 1, carrying out succinylation reaction, and carrying out ultrasonic treatment and dialysis under the condition that the ultrasonic power is 200-600W to obtain the double modified yeast protein purified product. Modified yeast protein molecules in the double-modified yeast protein purified product are promoted to generate specific conformational change and interaction through controlled thermal induction technology treatment, and the double-modified yeast protein thermal induction gel product with good gel performance, transparency, water binding capacity and gel strength is prepared.